Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions to Meet Increase in Investigational Drug Demand for Ongoing and Planned Clinical Trials

New supply agreement includes additional lots of intermediate drug product to support the manufacture of the rhenium (¹⁸⁶Re) obisbemeda radiotherapeutic

AUSTIN, Texas, May 02, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced an expansion of its collaboration with Piramal Pharma Solutions (PPS) to produce additional cGMP liposome intermediate drug product to meet the increase in demand for its lead investigational targeted radiotherapeutic, rhenium (¹⁸⁶Re) obisbemeda, for ongoing and planned clinical trials.

The new supply agreement builds on the Master Services Agreement which the Company and PPS entered into in 2021 for the development, manufacture and supply of rhenium (¹⁸⁶Re) obisbemeda.

“We significantly grew our clinical trial programs for central nervous system cancers in 2022 and we expect to continue this momentum into 2023,” said Marc H. Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics. “Our strategic partnership with PPS will support our robust supply chain and manufacturing processes to keep ahead of our planned clinical development expansion and lay the groundwork for commercialization in the future.”

“The expansion of our collaboration with Plus Therapeutics validates the breadth and scale of our capabilities as a leading CDMO,” said Peter DeYoung, Chief Executive Officer of Piramal Pharma Solutions. “Our services allow us to deliver solutions that benefit our partners and ultimately patients.”

About Rhenium (¹⁸⁶Re) Obisbemeda

Rhenium (¹⁸⁶Re) obisbemeda is a novel injectable radiotherapy specifically formulated to deliver highly targeted high dose radiation in CNS tumors in a safe, effective and convenient manner to optimize patient outcomes. Rhenium (¹⁸⁶Re) obisbemeda has the potential to reduce risks and improve outcomes for CNS cancer patients, versus currently approved therapies, with a more targeted and potent radiation dose. Rhenium is an ideal radioisotope for CNS therapeutic applications due to its short half-life, beta energy for destroying cancerous tissue and gamma energy for live imaging.